Reuters logo
3 months ago
BRIEF-Protagonist Therapeutics receives $1.34 mln SBIR funding for development of biomarkers
May 24, 2017 / 12:08 PM / 3 months ago

BRIEF-Protagonist Therapeutics receives $1.34 mln SBIR funding for development of biomarkers

May 24 (Reuters) - Protagonist Therapeutics Inc:

* Protagonist Therapeutics Inc - receives $1.34 million SBIR funding for development of biomarkers of il-23 receptor antagonist activity

* Protagonist Therapeutics Inc - company expects to initiate human clinical testing of PTG-200 in second half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below